April 25, 2001--Rosetta Inpharmatics, Inc. (Nasdaq:RSTA - news) today announced that Biogen, Inc. (Nasdaq:BGEN - news) has licensed the Rosetta Resolver(TM) Gene Expression Data Analysis System.
The Rosetta Resolver system is an enterprise bioinformatics system for gene expression research developed by Rosetta Inpharmatics and exclusively distributed by Agilent Technologies, Inc. (NYSE:A - news). The Rosetta Resolver system can be used with a wide variety of DNA chip technologies, including Affymetrix GeneChip®and Agilent DNA microarrays.
Biogen, the world's oldest independent biopharmaceutical company, is principally engaged in discovering and developing drugs for human health care through genetic engineering. The Rosetta Resolver system will be used to generate greater efficiencies in Biogen's drug discovery processes by enabling faster, more powerful management and analysis of Biogen's gene expression data.
``We are pleased to announce our first new licensee of version 2.0 of the Rosetta Resolver system,'' stated Stephen H. Friend, M.D., Ph.D., president and CEO of Rosetta Inpharmatics. ``The latest version of the system is geared specifically to organizations like Biogen, with expertise in gene expression research and a need for high-throughput analysis of Affymetrix GeneChip and other types of microarray data. The Rosetta Resolver system 2.0 can store and analyze large quantities of Affymetrix GeneChip data and offer the statistical rigor and high performance required for multidimensional analysis and visualization of these data.'' ... |
